ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2490

The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype

Meital Yerushalmi1, Osvaldo Espin-Garcia 2, Justine (Yang) Ye 3, Remy Pollock 4, Sara Rahmati 3, Lihi Eder 5, Mark Silverberg 6 and Vinod Chandran 7, 1University of Toronto, University Health Network, Toronto, ON, Canada, 2Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4Krembil Research Institute, University Health Network, Toronto, Canada, 5Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, 6Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7University Health Network, University of Toronto, Toronto, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: genetics and human leukocyte antigens (HLA), microbiome, psoriasis, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis is an inflammatory skin disease. Psoriatic arthritis (PsA) is an inflammatory arthritis that affects 30% of psoriasis patients. The heterogeneity of psoriatic disease (PsD- psoriasis and PsA) is partly explained by genetic heterogeneity: human leukocyte antigen (HLA)-C*06 is the strongest genetic risk factor for psoriasis without arthritis (PsC), while HLA-B*27 and other HLA-B alleles are more strongly associated with PsA. Yet, PsD pathogenesis is not fully understood, inspiring an interest in the role of an important environmental factor: the microbiome. We aimed to characterize the cutaneous microbiome of psoriatic plaques and compare its diversity between PsC and PsA patients and between the major PsD-associated HLA alleles.

Methods: Skin swabs were obtained from a psoriatic lesion on the extensor aspect of the elbow or knee, and from unaffected skin on the contralateral joint in PsC patients (psoriasis diagnosed by a dermatologist, evaluated by a rheumatologist to exclude PsA) and PsA patients satisfying CASPAR criteria. Control samples were taken from matched sites in healthy subjects. PsA patients were evaluated by a rheumatologist using a standard protocol to determine the number of affected joints, peripheral and/or axial joint involvement. Subsequently, microbial DNA was isolated from the swab samples, and high-throughput 16S ribosomal DNA sequencing was utilized to characterize the cutaneous microbiota. Molecular HLA Class I typing was done from DNA obtained from peripheral blood, and subjects were classified as being HLA-C*06 positive, HLA-B*27 positive or HLA-C*06 and -B*27 negative (termed double negative). All study subjects were Caucasian. Dada2 pipeline was used in the bioinformatic analysis to infer unique amplicon sequences from raw reads and remove chimeric sequences. QIIME v.1.9.1 was used to assign taxonomy with reference to an internally-designed 16S database, and to compute alpha-diversity. Biostatistical analysis was performed in R.

Results: We recruited 34 healthy controls (59% male), 55 PsC patients (47% male), and 136 PsA patients (63% male). 38 PsC and 90 PsA patients were included in this analysis after excluding subjects with recent use of topical ointments (≤7 days), antibiotics (≤3 months), and other related treatments. Linear model demonstrated that alpha diversity was significantly higher in lesional compared to unaffected samples in all PsD patients, as measured by Shannon diversity index (p=0.0106). However, there was no significant difference in lesional diversity between PsA and PsC patients (p=0.2244) (Figure 1). Interestingly, while there was no significant difference in alpha diversity between lesional swabs from HLA-B*27-positive compared to double negative patients (p=0.1401), it was shown to be significantly higher in lesional swabs from HLA-C*06-positive patients compared with both HLA-B*27-positive patients (p=0.0066) and double negative patients (p=0.0331) (Figure 2) by analysis of variance with Tukey’s correction for multiple comparisons.

Conclusion: The cutaneous lesional microbial diversity of patients with psoriatic disease may be influenced by the HLA-C*06 but not –B*27 alleles.


Disclosure: M. Yerushalmi, None; O. Espin-Garcia, None; J. Ye, None; R. Pollock, None; S. Rahmati, None; L. Eder, Abbvie, 2, 5, 8, Celgene, 5, Janssen, 5, Lily, 2, 5, Novartis, 2, 5, Pfizer, 2, 8, UCB, 2; M. Silverberg, None; V. Chandran, None.

To cite this abstract in AMA style:

Yerushalmi M, Espin-Garcia O, Ye J, Pollock R, Rahmati S, Eder L, Silverberg M, Chandran V. The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-cutaneous-microbiome-of-psoriatic-disease-is-influenced-by-disease-susceptibility-hla-alleles-but-not-clinical-phenotype/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-cutaneous-microbiome-of-psoriatic-disease-is-influenced-by-disease-susceptibility-hla-alleles-but-not-clinical-phenotype/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology